SAB Biotherapeutics Company Insiders
| SABSW Stock | USD 0.04 0.0008 2.05% |
SAB Biotherapeutics employs about 57 people. The company is managed by 9 executives with a total tenure of roughly 133 years, averaging almost 14.0 years of service per executive, having 6.33 employees per reported executive. Recap of SAB Biotherapeutics' management performance can provide insight into the venture performance.
SAB |
SAB Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.788) % which means that it has lost $0.788 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7473) %, meaning that it generated substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.SAB Biotherapeutics Workforce Comparison
SAB Biotherapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 834. SAB Biotherapeutics holds roughly 57.0 in number of employees claiming about 7% of equities under Health Care industry.
SAB Biotherapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SAB Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SAB Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, SAB Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ellias Helen K. over three months ago Discretionary transaction by Ellias Helen K. of 2857142 shares of SAB Biotherapeutics at 0.63 subject to Rule 16b-3 | ||
Moin Andrew over three months ago Discretionary transaction by Moin Andrew of 2747097 shares of SAB Biotherapeutics at 0.63 subject to Rule 16b-3 |
SAB Biotherapeutics Notable Stakeholders
A SAB Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as SAB Biotherapeutics often face trade-offs trying to please all of them. SAB Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting SAB Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Edward DVM | CoFounder Observer | Profile | |
| Samuel Reich | Executive Chairman | Profile | |
| Eddie Sullivan | President CoFounder | Profile | |
| Michael King | EVP CFO | Profile | |
| Christoph MBA | Executive COO | Profile | |
| Christine MBA | CoFounder Director | Profile | |
| MD MBA | Executive Officer | Profile | |
| Mark Conley | Interim Officer | Profile | |
| Carlos Carillo | Senior Affairs | Profile |
About SAB Biotherapeutics Management Performance
The success or failure of an entity such as SAB Biotherapeutics often depends on how effective the management is. SAB Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of SAB management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the SAB management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in SAB Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SAB Biotherapeutics. Check SAB Biotherapeutics' Beneish M Score to see the likelihood of SAB Biotherapeutics' management manipulating its earnings.
SAB Biotherapeutics Workforce Analysis
Traditionally, organizations such as SAB Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare SAB Biotherapeutics within its industry.SAB Biotherapeutics Manpower Efficiency
Return on SAB Biotherapeutics Manpower
| Revenue Per Employee | 39.3K | |
| Revenue Per Executive | 248.8K | |
| Net Loss Per Employee | 740.2K | |
| Net Loss Per Executive | 4.7M | |
| Working Capital Per Employee | 843.7K | |
| Working Capital Per Executive | 5.3M |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.